Aldosterone synthase inhibitor is a highly anticipated drug for cardio-metabolic indications. The drug will selectively inhibit synthesis of hormone aldosterone to manage deleterious effects of its excess.

We are targeting a mycobacterial cytochromes P450 for treatment of tuberculosis infection, including its drug resistant forms.

Additional value generation activity via drug discovery in diversified indications and international scientific collaborations.